Physician profile
George Salem
NPI 1659711356
$1,158,578.25
in general payments reported to CMS, 2019-2025
18 companies · $286K in 2025
The $286K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.27 · 2021: $57K · 2022: $220K · 2023: $291K · 2024: $304K · 2025: $286K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $715K · Travel and Lodging: $124K · Consulting Fee: $31K · Food and Beverage: $10K · Honoraria: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $714,612.76 |
| Travel and Lodging | $124,303.04 |
| Consulting Fee | $31,322.50 |
| Food and Beverage | $10,093.50 |
| Honoraria | $1,206.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370,874.73 | 2021-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $288,733.98 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $215,058.24 | 2023-2025 | Omvoh |
| Janssen Biotech, INC. | $178,877.49 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $69,503.41 | 2023-2025 | Entyvio |
| Celltrion USA INC. | $17,757.42 | 2024-2025 | Zymfentra |
| Pfizer INC. | $14,831.86 | 2021-2025 | |
| Celgene Corporation | $2,462.26 | 2019-2024 | Zeposia |
| Medtronic, INC. | $155.38 | 2022 | |
| Erbe USA INC | $84.89 | 2023 | Erbe Vio3 |
| Braintree Laboratories, INC. | $71.52 | 2021 | |
| Genzyme Corporation | $57.79 | 2022-2025 | |
| Daiichi Sankyo INC. | $37.18 | 2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $23.31 | 2025 | Dupixent |
| W. L. Gore & Associates, INC. | $21.31 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $16.52 | 2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.